Andrea Sabens Sells 386 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) CAO Andrea Sabens sold 386 shares of Lantheus stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $71.58, for a total transaction of $27,629.88. Following the completion of the transaction, the chief accounting officer now directly owns 62,290 shares in the company, valued at approximately $4,458,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Andrea Sabens also recently made the following trade(s):

• On Monday, March 6th, Andrea Sabens sold 7,705 shares of Lantheus stock. The shares were sold at an average price of $72.56, for a total transaction of $559,074.80.
• On Tuesday, January 17th, Andrea Sabens sold 386 shares of Lantheus stock. The shares were sold at an average price of $52.97, for a total transaction of $20,446.42.

Lantheus Price Performance

Shares of LNTH opened at $77.84 on Friday. The company has a market cap of $5.26 billion, a price-to-earnings ratio of 228.94 and a beta of 0.64. Lantheus Holdings, Inc. has a 1-year low of $47.46 and a 1-year high of $87.47. The company’s fifty day simple moving average is $62.11 and its 200 day simple moving average is $63.82. The company has a current ratio of 2.74, a quick ratio of 2.59 and a debt-to-equity ratio of 1.25.

Lantheus (NASDAQ:LNTH – Get Rating) last issued its earnings results on Thursday, February 23rd. The medical equipment provider reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.41. The business had revenue of $263.17 million for the quarter, compared to the consensus estimate of $244.61 million. Lantheus had a net margin of 3.00% and a return on equity of 51.60%. On average, research analysts forecast that Lantheus Holdings, Inc. will post 4.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lantheus

A number of institutional investors have recently added to or reduced their stakes in LNTH. Fairfield Bush & CO. acquired a new position in Lantheus during the first quarter worth $177,000. Raymond James & Associates acquired a new position in shares of Lantheus in the first quarter valued at $856,000. Bank of New York Mellon Corp increased its holdings in shares of Lantheus by 2.7% in the first quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock valued at $34,791,000 after purchasing an additional 16,422 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Lantheus by 14.4% in the first quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider’s stock valued at $1,064,000 after purchasing an additional 2,427 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new position in shares of Lantheus in the first quarter valued at $354,000. 97.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on LNTH. JMP Securities began coverage on shares of Lantheus in a research note on Wednesday, March 8th. They issued an “outperform” rating and a $120.00 price target on the stock. Mizuho boosted their price objective on shares of Lantheus from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, February 24th. StockNews.com began coverage on shares of Lantheus in a research report on Thursday. They issued a “hold” rating on the stock. Finally, SVB Leerink began coverage on shares of Lantheus in a research report on Wednesday, November 30th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $107.33.

Lantheus Company Profile

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.